Uppsala-based Readily Diagnostics has received a grant of approximately USD 970,000 (about SEK 9 million) from the Gates Foundation to develop a low-cost point-of-care test for chlamydia, gonorrhea and trichomoniasis, aimed at low-resource settings.

Lytix Biopharma has received FDA feedback on its proposed registrational Phase III trial design for ruxotemitide (LTX-315) in patients with resectable high-risk melanoma, with no objections raised – removing a key source of regulatory uncertainty as the company seeks a partner to fund and run the study.

The company has received an indicative offer for all shares in the company.

The company has signed a distribution agreement with Malaysian medical device distributor OneMedik for its Glycosorb ABO product, extending the company’s international footprint into a new Southeast Asian market.

Episurf Medical has concluded the strategic review of its medtech operations and will now pursue an orderly wind-down of that business, completing its transformation into a pure-play Nordic property company.

Finnish medtech company Nexstim has received an order for its latest-generation NBS 6 navigated brain stimulation system from an existing hospital customer in Europe, as the customer upgrades from an earlier-generation platform.

Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible Canadian patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, BioArctic’s partner Eisai announced. The Swedish biotech invented the antibody and holds commercialisation rights to it in the Nordic region.

The company reported H1 2026 sales revenue up 35.2 percent year-on-year, alongside new data on its psoriasis drug candidate HRO350 that it says complement earlier results from its HeROPA trial.

Alvotech’s Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio administered via prefilled syringe or autoinjector, has been accepted for review by the U.S. Food and Drug Administration.

Professor Mia Phillipson, co-founder of Ilya Pharma, is one of this year’s recipients of the Olof Rudbeck Medals.

Researchers at the University of Turku, working with France’s Gustave Roussy Institute, have identified a molecular mechanism that lets an aggressive subtype of colorectal cancer shield itself from chemotherapy and spread through the abdominal cavity – and shown that antibodies already used against other cancers can disrupt the process.

The Lundbeck Foundation has awarded DKK 78 million to a pan-Nordic centre that will focus on research into the glymphatic system.